Personalized medicine in breast cancer: a step forward

Alejandro Martin Sanchez, Gianluca Franceschini, Daniela Terribile, Sabatino D’Archi, Lorenzo Scardina, Riccardo Masetti


We have read with great interest the article by Kim et al., comparing the prognostic value of the AJCC eighth edition of the TNM classification for breast cancer (BC) with the previous one, in a retrospective series of 2,790 stage I-III BC patients with a median follow up of 116.2 months (1).